Cytokinetics Inc financial data

Symbol
CYTK on Nasdaq
Location
350 Oyster Point Boulevard, ., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 641 % -22.7%
Debt-to-equity -513 % +33.2%
Return On Equity 233 % -30.5%
Return On Assets -56.5 % -12.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 122M shares +3.6%
Common Stock, Shares, Outstanding 118M shares +16.3%
Entity Public Float 5.6B USD +180%
Common Stock, Value, Issued 122K USD +3.39%
Weighted Average Number of Shares Outstanding, Basic 120K shares +1.95%
Weighted Average Number of Shares Outstanding, Diluted 120K shares +1.95%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 87.2M USD +2609%
Research and Development Expense 405M USD +22.5%
General and Administrative Expense 255M USD +29.3%
Operating Income (Loss) -573M USD -9.21%
Nonoperating Income (Expense) 52M USD +17.8%
Net Income (Loss) Attributable to Parent -752M USD -30.5%
Earnings Per Share, Basic -6 USD/shares -16.9%
Earnings Per Share, Diluted -6 USD/shares -16.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 225M USD +381%
Cash, Cash Equivalents, and Short-term Investments 1.3B USD 0%
Accounts Receivable, after Allowance for Credit Loss, Current 1.81M USD +641%
Assets, Current 977M USD -4.05%
Property, Plant and Equipment, Net 76M USD +18.3%
Operating Lease, Right-of-Use Asset 77.6M USD +1.62%
Other Assets, Noncurrent 16.8M USD +118%
Assets 1.44B USD +0.04%
Accounts Payable, Current 22.1M USD +90.7%
Employee-related Liabilities, Current 33.2M USD +19.1%
Accrued Liabilities, Current 61.6M USD +23.7%
Liabilities, Current 142M USD +29.4%
Operating Lease, Liability, Noncurrent 111M USD -3.57%
Other Liabilities, Noncurrent 1.61M USD
Liabilities 1.96B USD +35%
Accumulated Other Comprehensive Income (Loss), Net of Tax 34K USD -99.4%
Retained Earnings (Accumulated Deficit) -3.3B USD -29.5%
Stockholders' Equity Attributable to Parent -521M USD -3646%
Liabilities and Equity 1.44B USD +0.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -132M USD -1.63%
Net Cash Provided by (Used in) Financing Activities 4.75M USD -95.4%
Net Cash Provided by (Used in) Investing Activities 106M USD +225%
Common Stock, Shares Authorized 163M shares 0%
Common Stock, Shares, Issued 118M shares +16.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.2M USD -405%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 229M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 9.65M USD -5.48%
Deferred Tax Assets, Valuation Allowance 713M USD +24.5%
Deferred Tax Assets, Gross 735M USD +23.2%
Operating Lease, Liability 132M USD -4.89%
Payments to Acquire Property, Plant, and Equipment 5.66M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -757M USD -32.8%
Lessee, Operating Lease, Liability, to be Paid 191M USD -8.94%
Property, Plant and Equipment, Gross 103M USD +6.07%
Operating Lease, Liability, Current 20.6M USD +9.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.6M USD +4.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 59.4M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.5M USD +1.66%
Deferred Tax Assets, Operating Loss Carryforwards 283M USD +22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 31M USD +22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.7M USD +1.09%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.3M USD -1.33%
Share-based Payment Arrangement, Expense 108M USD +18.6%
Interest Expense 11.4M USD +27.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%